Managed Entry

Managed Entry

Print page
 
The HSC Board supports the timely introduction of effective new medicines that allow people in Northern Ireland to benefit from advances in medical treatment.
 
The HSC Board has been developing new arrangements for improving the process by which  new medicines should be adopted for use (managed entry process), with the aim of ensuring timely and equitable access to those medicines for which there is an evidence base on efficacy and cost-effectiveness. These new arrangements came into effect from 1 April 2014. Details of the new arrangements can be found here.
 
In drawing on the evidence available we look to recognised bodies in the UK. In particular we adopt, as policy, the decisions made by the National Institute for Health and Care Excellence (NICE). In advance of, or in the absence of, a published NICE determination the Board will seek and potentially apply decisions made by other well established UK bodies
 
 

What does this advice mean for prescribers?

While we are making new drugs available prescribers in Northern Ireland are expected to adhere to the NI Formulary for a broad range of conditions. The managed entry process will specify either:
 
 “Accepted for use”:  New medicines with limited long-term safety and outcome data and should only be prescribed in the particular circumstances outlined.
 
“Not accepted for use”: We are asking that drugs not accepted for use in Northern Ireland should not  be prescribed in Primary or Secondary Care for the indications specifed.1  Drugs that are not accepted for use can, however, be provided in particular circumstances via the Individual Funding Route via Secondary Care.
 
1. People currently receiving such drugs should be able to continue therapy until they and their clinician consider it clinically appropriate to stop.